typically combine drug formulations (most often parenteral) with a mechanical delivery system.

The regulatory frameworks for combination products encompass guidelines from multiple authorities:

• US FDA: Combination products are regulated under 21 CFR Parts 210 and 211 for pharmaceuticals, incorporating device requirements per 21 CFR Part 820 when applicable.
• EU EMA and EU GMP Volume 4: The pharmaceutical component controls align with EU GMP Annex 1 and Annex 15, while device requirements relate to the Medical Devices Regulation (MDR) and ISO standards.
• MHRA and PIC/S Guidelines: These provide harmonized guidance consistent with EU and FDA approaches.

Quality systems for combination products hence must integrate pharmaceutical GMP for drug manufacturing and Quality Management System (QMS) elements from device regulations. Notably, FDA’s Quality System Inspection Technique guide offers insights on overseeing device components alongside drug manufacturing.

Pharmaceutical dosage forms in combination products can include:

• Solid oral formulations: tablets or capsules prefilled or enclosed within the device.
• Parenteral formulations: sterile solutions, suspensions, or lyophilized powders delivered by injection.
• Topical delivery: less common but relevant in certain device-assisted skin applications.

This variability necessitates established GMP controls tailored specifically to the dosage form and manufacturing complexity.

2. Quality Management and Documentation for Combination Products

A robust Quality Management System (QMS) integrating drug and device requirements is the foundation. It must cover all phases from design and development through manufacturing, packaging, labeling, and distribution. Regulatory authorities expect documented procedures demonstrating traceability, control, and risk management for combined drug-device entities.

Key elements include:

• Design Control: Per ICH Q8 and ISO 13485, establish and maintain design and development protocols. Document design inputs, outputs, verification, validation, and risk management.
• Change Control: Consider changes affecting both drug formulation and device components. Evaluate potential impacts per EU GMP Volume 4 Annex 15 principles.
• Supplier Qualification: GMP applies not only to drug manufacturers but also to device suppliers. Qualification and auditing must confirm compliance with appropriate standards (e.g., FDA QSR for devices, ISO 13485).
• Batch Record and Device Assembly Records: Combined batch manufacturing records must include drug formulation steps and device assembly or integration procedures.
• Training and Competency: Personnel must be trained both in drug GMP and device handling, assembly, and testing, ensuring awareness of cross-disciplinary risks.

Proper documentation supports regulatory inspections by FDA, EMA, or MHRA, particularly during stringent audits focused on combination product GMP compliance. Transparency and data integrity are paramount throughout the product lifecycle.

3. Manufacturing Considerations for Dosage Forms in Pen and Auto-Injectors

Pen injectors and auto-injectors may deliver one or more dosage forms, each posing unique manufacturing challenges from a GMP viewpoint. The following sections highlight critical manufacturing controls relative to solid oral, parenteral, and topical dosage forms integrated in these devices.

3.1 Solid Oral Dosage Forms

When combination products contain tablets or capsules (solid oral dosage forms), traditional tablet manufacturing and capsule GMP requirements apply with additional emphasis on integration into the delivery device. Key GMP aspects include:

• Component Quality Control: Raw materials, excipients, and active pharmaceutical ingredients (APIs) must meet pharmacopeial or internal specifications.
• Process Validation: Tablet compression or capsule filling processes require qualification and validation, ensuring content uniformity and stability.
• Device Compatibility: Evaluate potential impacts of tablet or capsule fill weight and hardness on device fit, activation force, and integrity.
• Packaging Control: Blister packs or cartridge inserts must withstand assembly into pen injectors without damage, preserving drug stability and sterility (if applicable).

Although rare, some combination products incorporate solid oral dosage forms designed for controlled release via device actuation, requiring even tighter coordination between formulation scientists and device engineers.

3.2 Parenteral (Sterile Injectable) Dosage Forms

Parenteral formulations are the most common drug components in pen injectors and auto-injectors. Stringent GMP controls for sterile injectables must be harmonized with device manufacturing and assembly:

• Sterile Manufacturing Environment: Cleanrooms must comply with classifications such as EU GMP Annex 1 Grade A/B or FDA aseptic processing guidelines.
• Component Sterility and Integrity: Containers (cartridges or prefilled syringes) undergo sterilization by steam, radiation, or aseptic filling.
• Assurance of Container Closure: The device-drug interface must maintain sterility during device assembly and throughout shelf life.
• Process Validation: Media fills or simulated aseptic runs validate the manufacturing process’s ability to prevent microbial contamination.
• Integration and Assembly Controls: Automated or manual processes assembling the drug container into the pen or auto-injector device must mitigate contamination risks and preserve sterile barriers.

Risk management per ICH Q9 principles guides mitigation strategies, including environmental monitoring, equipment qualification, and personnel gowning controls designed specifically for combination sterile products. The evolving WHO GMP guidelines for sterile pharmaceutical products also emphasize these aspects.

3.3 Topical Dosage Forms

Though less common in pen injector/auto-injector formats, topical formulations (creams, gels) may be combined with applicator devices. GMP considerations include:

• Physical and Microbial Quality: Ensuring homogeneity, preservative efficacy, and absence of microbial contamination per topical product standards.
• Device Compatibility Testing: Interaction between formulation and device materials must be verified to prevent leaching or degradation.
• Filling and Assembly: Closed-system filling may be needed to reduce microbial ingress during production and device loading.

The integrative control of dosage form and device remains critical to confirming consistent product performance and regulatory compliance.

4. Device Assembly, Integration and Final Product Release

Assembly and integration steps transform drug components into the final combination product ready for market release, presenting rigorous GMP challenges that require cross-functional collaboration.

• Device Component Quality Assurance: Raw materials, subassemblies, and finished parts for pen injectors and auto-injectors must comply with relevant standards and be subjected to incoming inspection per device GMP requirements.
• Controlled Assembly Processes: Procedures for assembling drug-filled cartridges or syringes into the delivery device must be validated. Controls mitigate contamination risks and device malfunctions.
• In-Process Testing: Functional testing of injection force, dose accuracy, needle deployment, and device safety features verify integrated component performance.
• Final Product Quality Control (Release Testing): Testing includes identity, potency, sterility (for parenteral drugs), and device functionality to comply with specifications before batch release.
• Traceability and Serialization: Each combination product batch or unit requires comprehensive traceability through unique device identification (UDI) and batch numbering systems per regulatory guidance.

Manufacturers must thoroughly document all production and testing activities to support regulatory inspections and maintain compliance with evolving quality system expectations.

5. Post-Market Surveillance and Continuous Improvement

GMP does not stop at product release for combination products. Post-market surveillance supports ongoing compliance and patient safety:

• Complaint Handling: Systems must capture and investigate complaints related to both drug performance and device malfunctions.
• Adverse Event Reporting: Integration with pharmacovigilance and device vigilance systems ensures timely regulatory notifications.
• Periodic Product Review (PPR): Reviews include manufacturing data, quality metrics, complaint trends, and stability monitoring to identify improvement opportunities.
• Change Management: Changes in manufacturing processes, materials, or device design require reevaluation and regulatory notification following ICH and EU GMP Annex 15 guidance.

Continuous improvement culture and risk-based quality management maintain product reliability across the supply chain.

Conclusion

The manufacture of pen injectors and auto-injectors as combination products demands a rigorous, integrated GMP approach tailored to the pharmaceutical dosage forms involved. By meticulously implementing design controls, manufacturing best practices, device assembly protocols, and comprehensive quality management systems, pharmaceutical manufacturers can ensure compliance with FDA, EMA, MHRA, PIC/S, and WHO requirements. Attention to solid oral, parenteral, and topical dosage form specifics coupled with effective post-market surveillance assures patient safety, product quality, and regulatory conformity.

Professionals engaged in clinical operations, regulatory affairs, medical affairs, and pharmaceutical manufacturing will benefit from adopting these GMP principles to navigate the complexities of combination product development and commercial production successfully.